Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer
Related Posts
Nguyen J, Tun N, Burley N, Bolos D. Navigating Complexity: A Case Study on Hemophagocytic Lymphohistiocytosis Diagnosis and Management Challenges. Cureus. 2024 May 4;16(5):e59628. doi:[...]
Cai J, Varda M, Sin D, Overby H, Yeh JJ. Unusual painful pelvic masses: Extramedullary hematopoiesis with extramedullary multiple myeloma. Clin Case Rep. 2024 May[...]
Shang H, Ding Y, Venkateswaran V, Boulier K, Kathuria-Prakash N, Malidarreh PB, Luber JM, Pasaniuc B. Generalizability of PGS313 for breast cancer risk in a Los[...]